Oxurion Receives Transparency Notification from Fidelity

Leuven, BELGIUM, Boston, MA, US – November 4, 2022 – 7 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical firm creating subsequent technology normal of care ophthalmic therapies, with scientific stage property in vascular retinal issues, right this moment introduced that, pursuant to Belgian Transparency laws¹ it has acquired transparency notification following the issuance of latest shares pursuant to the Capital Commitment entered into with Negma Group.

Oxurion acquired a transparency notification from Fidelity Management & Research Company LLC, indicating that by advantage of a downward passive crossing of a threshold, its 3,128,819 widespread shares have crossed beneath the 5% threshold.

Content of the Fidelity Notification

Reason of the notification

Passive crossing of a threshold

Notifications by

A mum or dad enterprise or a controlling particular person

Threshold that’s crossed

5%

Denominator

66,675,765

Notified particulars

See Annex 1

Chain of managed undertakings by way of which the holding is successfully held

Fidelity Management & Research Company LLC is managed by FMR LLC.

FMR LLC just isn’t a managed entity

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical firm creating subsequent technology normal of care ophthalmic therapies, that are designed to enhance and higher protect imaginative and prescient in sufferers with retinal issues together with diabetic macular edema (DME), the main reason behind imaginative and prescient loss in working-age folks, in addition to different circumstances. Oxurion intends to play an essential function within the therapy of retinal issues, together with the profitable improvement of THR-149, its novel therapeutic for the therapy of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a possible new normal of look after the as much as 50% of DME sufferers exhibiting suboptimal response to anti-VEGF remedy. Oxurion is headquartered in Leuven, Belgium, with company operations in Boston, MA. More data is on the market at www.oxurion.com.

Important details about forward-looking statements

Certain statements on this press launch could also be thought-about “forward-looking”. Such forward-looking statements are primarily based on present expectations, and, accordingly, entail and are influenced by varied dangers and uncertainties. The Company subsequently can not present any assurance that such forward-looking statements will materialize and doesn’t assume any obligation to replace or revise any forward-looking assertion, whether or not because of new data, future occasions, or another motive. Additional data regarding dangers and uncertainties affecting the business and different elements that might trigger precise outcomes to vary materially from any forward-looking assertion is contained within the Company’s Annual Report. This press launch doesn’t represent a suggestion or invitation for the sale or buy of securities or property of Oxurion in any jurisdiction. No securities of Oxurion could also be provided or bought throughout the United States with out registration beneath the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any relevant U.S. state securities legal guidelines.

For additional data please contact:

ANNEX 1

________

1. Article 14, first paragraph, of the Law of two May 2007 on disclosure of main holdings.

• OXUR Transparency Notification (EN) 2022.1104